The present disclosure relates to compositions and methods relating to the characterization and function of CCR6. Specifically, the present disclosure provides transgenic animals comprising disruptions in a CCR6 gene and methods of treating diseases conditions, such as pain, inflammatory bowel disease, rheumatoid arthritis and contact dermatitis. The present disclosure further relates to agents that modulate CCR6 and methods of screening for agents that modulate CCR6 for the treatment of diseases and conditions such as pain, inflammatory bowel disease, rheumatoid arthritis and contact dermatitis.